Ginkgo insider plans 2,200-share sale, $14.7K

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. insider Austin Che filed a notice of proposed sale of 2,200 Class A shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $14,652.00 and 55,383,808 Class A shares reported outstanding as of August 17, 2026.

The shares derive from prior restricted stock vesting awards of 20 and 2,180 Class A shares that vested on October 10 and October 12, 2022, respectively. The filing also lists a sale of 2,200 Class A shares on June 10, 2026 for $17,732.00 during the past three months.

Key Figures

Planned shares to be sold: 2,200 Class A shares Aggregate market value of planned sale: $14,652.00 Shares outstanding: 55,383,808 Class A shares +3 more

6 metrics

Planned shares to be sold 2,200 Class A shares Securities to be sold through Fidelity Brokerage Services LLC

Aggregate market value of planned sale $14,652.00 Reported value for the 2,200 Class A shares to be sold

Shares outstanding 55,383,808 Class A shares Reported outstanding as of August 17, 2026

Restricted stock vesting (Oct 10, 2022) 20 Class A shares Restricted stock vesting from issuer as compensation

Restricted stock vesting (Oct 12, 2022) 2,180 Class A shares Restricted stock vesting from issuer as compensation

Recent sale amount 2,200 Class A shares for $17,732.00 Securities sold during the past three months on June 10, 2026

Key Terms

Form 144, Restricted Stock Vesting, Compensation

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Restricted Stock Vesting | Issuer | | | 20 | 10/10/2022"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Compensation financial

"10/12/2022 | Compensation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ginkgo Bioworks (DNA) report in this Form 144 filing?

The filing reports a proposed sale of 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. by insider Austin Che. It lists the broker, expected aggregate value, prior restricted stock vesting awards, and a recent sale within the past three months.

How many Ginkgo Bioworks (DNA) shares does Austin Che plan to sell?

Austin Che plans to sell 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. The notice specifies this amount as the securities to be sold through Fidelity Brokerage Services LLC on the NYSE.

What is the expected value of the planned Ginkgo Bioworks (DNA) share sale?

The planned sale of 2,200 Class A shares has an aggregate market value of $14,652.00. This figure reflects the value reported for the proposed transaction in the notice of sale.

How many Ginkgo Bioworks (DNA) shares are reported outstanding in this filing?

The filing reports 55,383,808 Class A shares outstanding for Ginkgo Bioworks Holdings, Inc. This outstanding share count is stated as of August 17, 2026, serving as context for the proposed sale size.

What prior restricted stock vesting is disclosed for Ginkgo Bioworks (DNA) insider Austin Che?

Austin Che’s holdings include restricted stock awards of 20 and 2,180 Class A shares that vested on October 10, 2022 and October 12, 2022. These vestings are listed as compensation-related issuances from the issuer.

What recent sales of Ginkgo Bioworks (DNA) stock are reported for the past three months?

The filing lists a sale of 2,200 Class A shares of Ginkgo Bioworks Holdings, Inc. on June 10, 2026 for an aggregate value of $17,732.00. This is disclosed under securities sold during the past three months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 12:18 PM Accepted by SEC EDGAR 08/17/2026 - 12:18 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001882820
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ginkgo Bioworks Holdings, Inc.
SEC File Number	001-40097
Address of Issuer	27 DRYDOCK AVENUE 8TH FLOOR BOSTON MASSACHUSETTS 02210
Phone	(877) 442-5362
Name of Person for Whose Account the Securities are To Be Sold	Che Austin
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2200	14652.00	55383808	08/17/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	10/10/2022	Restricted Stock Vesting	Issuer			20	10/10/2022	Compensation
Class A	10/12/2022	Restricted Stock Vesting	Issuer			2180	10/12/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Austin Che 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	06/10/2026	2200	17732.00

144: Remarks and Signature

Remarks
Date of Notice	08/17/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/11/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Austin Che
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)